An idea is born, Simon and Michal lay the foundation in Basel, Switzerland
06/08/2023In collaboration with academic partners, RXcel has successfully conducted a proof-of-concept experiment, funded by Innosuisse. This study demonstrated a statistically significant difference of effector protein production in specific cell lines with and without CDKN2A, using fluorescent reporter constructs (eGFP). The underlying concept has been discussed with scientists in the relevant fields, who have expressed confidence in its potential.
01/03/2024We have begun building partnerships with highly experienced experts to help accelerate our mission. Private funding has enabled us to revalidate and optimize in vitro results in close collaboration with FHNW and the University of Prague.
01/01/2025In close collaboration with our academic partners, we are currently optimizing our target RNA, aiming to reach in vivo readiness by Q1 2026. This includes the integration of new RNA designs to build a versatile therapeutic platform, along with ongoing validation of the molecular mechanism and assessment of potential off-target effects. To advance into in vivo studies, additional funding will be required, and RXcel has initiated early-stage discussions to secure the necessary resources.
12/31/2025